TUDCA Supplements: Liver Claims, Dosage, Safety, and Label Guide

TUDCA stands for tauroursodeoxycholic acid and may also appear as tauro-ursodeoxycholic acid or ursodoxicoltaurine. It is related to, but not interchangeable with, ursodeoxycholic acid (UDCA).

TUDCA is a hydrophilic bile acid formed when ursodeoxycholic acid is conjugated with taurine. Human research has examined it mainly in specific liver diseases and as an experimental treatment in amyotrophic lateral sclerosis. Some small or older liver studies reported improvements in serum liver enzymes, but they did not establish general “liver detoxification”, protection from alcohol or anabolic steroids, or restoration of blocked bile ducts. A small ALS trial produced encouraging findings, but a later European phase III trial found no overall benefit. Supplement labels should therefore keep TUDCA claims narrow, clearly disclose the amount per serving and full daily serving, and avoid converting laboratory mechanisms into promises of organ repair. Vegan, animal-free, or source-specific claims require separate supporting documentation.

What is TUDCA?

TUDCA is the taurine-conjugated form of ursodeoxycholic acid. Both belong to the bile-acid family, but they differ in chemical form, absorption, metabolism, and the clinical products in which they have been studied.

Bile acids help the body process dietary fats and participate in signalling pathways involving the liver, intestine, and metabolism. TUDCA is relatively hydrophilic compared with several other bile acids, which helps explain research interest in cholestatic liver disease and cellular stress.

TUDCA is also described as a chemical chaperone because laboratory research suggests that it can reduce certain forms of endoplasmic-reticulum stress and influence cell-death pathways.

Most detailed evidence for these mechanisms comes from cells and animals. A mechanism does not demonstrate that a retail capsule repairs the liver, brain, retina, gallbladder, and digestive tract in humans.

TUDCA versus UDCA

UDCA and TUDCA are closely related, which makes evidence borrowing especially tempting. It is also scientifically careless.

UDCA has a much larger clinical literature and is used medically in selected cholestatic liver conditions. TUDCA is UDCA conjugated with taurine and has been tested separately in smaller clinical studies.

In a crossover study of 23 people with primary biliary cholangitis, participants received 500 mg per day of TUDCA and 500 mg per day of UDCA during separate six-month periods. Liver enzymes improved from baseline with both treatments, and no significant difference between the two bile acids was found. ^[2]

This suggests comparable short-term biochemical effects under that specific protocol. It does not mean that every result from a UDCA medicine can be reassigned to an over-the-counter TUDCA supplement.

What do human liver studies show?

TUDCA has been studied in several liver conditions, but much of the evidence is old, based on small samples, and focused on serum biochemical markers.

Primary biliary cholangitis dose study

A six-month randomized dose-response study enrolled 24 people with primary biliary cholangitis, historically called primary biliary cirrhosis. Participants received 500, 1,000, or 1,500 mg of TUDCA per day.

Serum liver enzyme levels decreased significantly after the first month in all three groups. No clear overall difference was found among the doses, although additional reductions over time occurred in the 1,000 and 1,500 mg groups. Diarrhoea was the only reported side effect. ^[1]

The trial did not include a placebo group and did not establish reduced mortality, fewer liver transplants, reversal of fibrosis, or relief of every symptom.

Chronic hepatitis C study

A multicentre placebo-controlled study randomized 150 people with chronic hepatitis C to 500 mg of TUDCA, 750 mg of TUDCA, or placebo for six months.

Aminotransferase levels decreased more with TUDCA than with placebo. ^[3]

Lower liver enzymes did not demonstrate clearance of hepatitis C, prevention of cirrhosis, or replacement of antiviral treatment. The study predates modern direct-acting antiviral therapy and should not be presented as a current hepatitis C treatment protocol.

Small cirrhosis comparison

A 2013 double-blind trial assigned 23 people with liver cirrhosis to 750 mg per day of either TUDCA or UDCA. Only 18 participants were included in the final analysis.

Several liver enzymes improved from baseline in the TUDCA group, but serum fibrosis markers did not improve significantly and convincing histological improvement was not demonstrated. The study compared TUDCA with UDCA rather than placebo. ^[4]

Is TUDCA a liver detox supplement?

“Detox” is not a defined outcome in the human TUDCA trials. Researchers measured enzymes, bile-acid composition, cholesterol, symptoms, or disease-specific function. They did not measure unspecified toxins being flushed from the body.

ALT and AST are markers that can change for many reasons. A reduction may be clinically useful in context, but it does not by itself prove that liver tissue regenerated or that long-term complications were prevented.

Claims such as “cleanses the liver”, “unclogs bile ducts”, “removes toxic bile sludge”, or “repairs the liver after a weekend” go beyond the human evidence.

Does TUDCA protect the liver during anabolic-steroid use?

TUDCA is popular in bodybuilding products intended for use during or after oral anabolic-steroid cycles. Controlled human trials have not established that TUDCA prevents steroid-induced liver injury.

The liver studies described above involved diagnosed diseases, not healthy athletes deliberately exposed to hepatotoxic drugs. Improvements in a cholestatic-disease trial cannot be assumed to make anabolic-steroid use safe.

A supplement should not claim that TUDCA keeps ALT or AST “in range”, prevents cholestasis, or protects against liver failure during a cycle without direct human evidence.

TUDCA also cannot determine whether abnormal liver tests reflect a drug reaction, viral hepatitis, gallstone obstruction, alcohol-related injury, fatty liver disease, muscle damage, or another cause.

Can TUDCA be taken with alcohol?

There is no controlled human trial establishing a rule that TUDCA must never be taken while alcohol is present, or that it should be taken the following morning to repair liver damage.

A frequently cited study examined ethanol, acetaldehyde, TUDCA, and UDCA in cultured human-derived liver cells. Results varied according to concentration, timing, and whether cells were pretreated or treated simultaneously. ^[8]

A cell-culture experiment cannot establish a safe schedule for drinking and supplement use in humans. It provides no basis for presenting TUDCA as protection before, during, or after alcohol consumption.

The responsible conclusion is not “take TUDCA the next morning”. It is that TUDCA has not been shown to neutralize alcohol-related liver risk.

Does TUDCA improve bile flow or dissolve gallstones?

TUDCA can alter bile-acid composition and has been studied in people with radiolucent gallstones. This does not mean that it functions as a general-purpose drain cleaner for the liver and gallbladder.

In a short dose-response study involving 33 people with radiolucent gallstones, TUDCA reduced biliary cholesterol saturation and increased the proportion of ursodeoxycholic acid in bile. ^[5]

The study measured bile composition over roughly four to six weeks. It did not demonstrate rapid pain relief, guaranteed stone dissolution, clearance of a blocked duct, or improved fat digestion in healthy users.

Much of the clinical gallstone-dissolution literature concerns UDCA, not ordinary TUDCA supplements. Even medical bile-acid treatment applies only to selected stone types and clinical circumstances.

Right-upper-abdominal pain, jaundice, fever, vomiting, dark urine, or pale stools can indicate conditions that require medical assessment. They should not be treated as proof that someone merely needs more bile flow.

Is TUDCA useful after gallbladder removal?

The absence of a gallbladder is not by itself an evidence-based indication for routine TUDCA supplementation.

After gallbladder removal, bile continues to be produced by the liver and enters the intestine without being stored in the gallbladder. Some people develop digestive symptoms, but those symptoms can have different causes.

We did not identify controlled human trials establishing that TUDCA routinely improves digestion, prevents bile problems, or is required after cholecystectomy.

Does TUDCA protect the brain or slow ALS?

TUDCA has been investigated as a possible neuroprotective treatment, particularly in amyotrophic lateral sclerosis. The full evidence is less encouraging than the early research alone suggests.

A small double-blind pilot study evaluated 34 people with ALS already taking riluzole. Participants received either placebo or 1 gram of TUDCA twice daily for 54 weeks.

The TUDCA group had a higher proportion of responders and a slower decline on selected functional analyses. The authors described the findings as preliminary. ^[6]

A later European phase III trial included 336 participants and evaluated 2 grams of TUDCA per day for up to 18 months.

According to the trial consortium’s non-peer-reviewed top-line results, TUDCA did not meet the primary endpoint. No significant benefit was found for the reported secondary endpoints, including survival and biomarkers. Treatment was generally well tolerated, with mainly mild gastrointestinal effects. ^[7]

TUDCA should therefore not be marketed as a clinically proven ALS or neurodegenerative-disease treatment.

Does TUDCA protect the eyes?

TUDCA has produced retinal-protection signals in cell cultures and animal models, including mouse models of retinal degeneration. ^[9]

Those findings are scientifically interesting, but controlled human trials have not established that oral TUDCA slows retinitis pigmentosa, protects vision, treats diabetic retinopathy, or prevents retinal degeneration.

A product should not use a mouse-retina experiment to promise human eye protection. The retina is complicated enough without making it responsible for translating supplement marketing.

TUDCA dosage: what human studies used

There is no established daily TUDCA dose for general liver support, bodybuilding, alcohol recovery, gallbladder health, digestion, eye health, or longevity.

Human research has used amounts such as:

• 500, 1,000, or 1,500 mg per day in a six-month primary biliary cholangitis study;
• 500 mg per day in a TUDCA-versus-UDCA crossover study;
• 500 or 750 mg per day in chronic hepatitis C;
• 750 mg per day in a small cirrhosis comparison;
• 2,000 mg per day in ALS trials.

These are disease-specific study protocols, not a single clinically effective range.

A 250 mg “general health” dose has not been validated simply because it is common in commercial capsules. Likewise, 1,000 or 2,000 mg should not receive automatic efficacy credit when the product’s claim has never been tested.

Should TUDCA be taken with a fatty meal?

Human TUDCA studies have used different dosing schedules, including divided doses and administration around meals.

There is no strong comparative evidence showing that every TUDCA supplement must be taken with dietary fat or that a fatty meal produces better clinical outcomes.

“Take with fat because TUDCA digests fat” is an appealing circular explanation, not a demonstrated universal dosing rule.

Side effects and safety limitations

TUDCA was generally well tolerated in the human trials discussed on this page. Gastrointestinal effects, particularly diarrhoea or loose stools, are among the most consistently reported problems.

The six-month primary biliary cholangitis study reported diarrhoea as the only side effect. The larger ALS phase III programme also described mostly mild gastrointestinal adverse effects.

These findings do not establish universal long-term safety for self-directed use in healthy people. Most clinical evidence concerns people under medical supervision with diagnosed liver or neurological disease.

Safety has not been established adequately during pregnancy, breastfeeding, childhood, or prolonged high-dose use outside a clinical setting.

Existing liver disease, suspected bile-duct obstruction, gallbladder symptoms, jaundice, or unexplained abnormal liver tests should not be self-managed with an online TUDCA protocol.

Source, authenticity, and purity claims

TUDCA has historical connections to bear bile, but modern commercial material may be produced through synthetic processes. A vegan or animal-free claim should still be supported by manufacturer documentation covering the active ingredient, capsule shell, and processing aids.

Price does not prove authenticity. A low-cost product is not automatically rice flour, and an expensive product is not automatically genuine.

Smell, bitterness, colour, or tasting the powder cannot verify molecular identity or purity. Sensory inspection is not a substitute for analytical chemistry.

More useful documentation includes:

• a batch-specific certificate of analysis;
• identity testing against an appropriate TUDCA reference standard;
• a quantitative assay such as validated HPLC or LC-MS;
• limits for related bile-acid impurities;
• and relevant contaminant and microbiological testing.

“99% purity” is meaningful only when the report identifies the batch, laboratory, method, specification, and result. A generic badge stating “third-party tested” does not establish either identity or clinical effectiveness.

Common TUDCA label red flags

The first red flag is “liver detox” language. Human studies measured disease-specific laboratory markers, not the flushing of undefined toxins.

The second is guaranteed protection during anabolic-steroid use. That claim lacks controlled human evidence.

The third is an alcohol timing protocol. Cell studies do not prove that TUDCA is protective during drinking or reparative the following morning.

The fourth is claiming that TUDCA dissolves any gallstone, clears blocked bile ducts, or treats right-sided abdominal pain.

The fifth is presenting animal retinal research as proof of human eye protection.

The sixth is citing the small positive ALS pilot while omitting the negative phase III result.

The seventh is automatic synergy claims, such as describing TUDCA and milk thistle as a complete liver-defence system. A combination requires evidence for the combination.

The eighth is using price, smell, or bitterness as an authenticity test.

The ninth is an unsupported “500% bile flow” number without a traceable human study and clearly defined measurement.

The tenth is hiding TUDCA inside a proprietary liver blend, making the actual amount impossible to compare with research.

How NutriDetector evaluates TUDCA supplements

NutriDetector checks whether the product clearly identifies TUDCA as the ingredient form, rather than combining it with UDCA, taurine, ox bile, or unspecified bile salts.

The analysis reviews the amount per serving, the number of servings recommended per day, and the total disclosed daily amount. If TUDCA is hidden inside a proprietary blend or the daily dose cannot be calculated from the label, that limitation remains visible.

The disclosed amount is compared with doses used in human studies, while keeping the study population and outcome in context. Matching a research dose does not automatically prove that a supplement will deliver the same result, particularly when the label promotes general liver support, alcohol recovery, bodybuilding protection, gallstone treatment, or neuroprotection.

NutriDetector also checks whether marketing claims are aligned with human evidence and whether important label information is missing or ambiguous. Higher doses are not treated as inherently better, and TUDCA does not receive automatic credit for broad “detox” or organ-protection claims.

A supplement label alone cannot verify molecular identity, purity, contamination testing, or batch authenticity. Those claims require separate, batch-specific manufacturer or laboratory documentation.

Evidence-based bottom line

TUDCA is a genuine biologically active bile acid with human clinical research, but that research is narrower than supplement marketing suggests.

Small and mostly older liver studies show that TUDCA can improve selected serum liver enzymes in diagnosed cholestatic or chronic liver conditions. They do not establish general liver detoxification, reversed fibrosis, protection during anabolic-steroid use, or recovery from alcohol.

Gallstone research shows changes in bile composition, not guaranteed stone dissolution or treatment of suspected obstruction. Eye-protection claims remain predominantly preclinical.

A small ALS pilot was encouraging, but a substantially larger phase III trial found no overall benefit. Any neuroprotection claim should include that result rather than preserving only the more marketable half of the evidence.

A trustworthy TUDCA label clearly identifies the ingredient, states the amount per serving and full daily serving, distinguishes TUDCA from UDCA and generic bile salts, and avoids presenting unverified purity or source claims as established facts. Identity, purity, and batch authenticity require documentation beyond the retail label.

FAQ: TUDCA supplements

What does TUDCA do?

TUDCA is a hydrophilic bile acid studied in selected liver diseases and experimental neurological settings. Some trials report changes in liver enzymes, but broad detoxification and organ-repair claims are not established.

Is TUDCA the same as UDCA?

No. TUDCA is the taurine-conjugated form of UDCA. They are closely related but have separate formulations, metabolism, clinical studies, and regulatory contexts.

Does TUDCA protect the liver during steroid cycles?

Controlled human trials have not shown that TUDCA prevents anabolic-steroid-related liver injury or makes oral steroid use safe.

Can TUDCA be taken with alcohol?

No human trial establishes a protective timing protocol during or after alcohol consumption. TUDCA should not be relied on to prevent or repair alcohol-related liver damage.

Does TUDCA dissolve gallstones?

TUDCA has altered bile composition in small human studies, but ordinary supplements have not been shown to dissolve every gallstone or treat bile-duct obstruction. Much of the medical dissolution evidence concerns UDCA.

Is TUDCA recommended after gallbladder removal?

Routine use after gallbladder removal has not been established in controlled human trials. The absence of a gallbladder is not by itself evidence of a TUDCA deficiency.

Does TUDCA help ALS?

A small pilot trial was encouraging, but a later European phase III trial did not meet its primary or secondary efficacy endpoints. TUDCA is not established as an effective ALS treatment.

Does TUDCA protect eyesight?

Retinal-protection findings come mainly from cells and animal models. Human clinical benefit for retinitis pigmentosa or other retinal diseases has not been established.

What dose of TUDCA was used in studies?

Liver studies used approximately 500 to 1,500 mg per day, while ALS trials used 2,000 mg per day. These were condition-specific protocols, not universal supplement recommendations.

How can you tell whether TUDCA is genuine?

Price, smell, colour, and taste cannot verify authenticity. Useful evidence includes batch-specific identity testing, quantitative assay results, related bile-acid impurity limits, and clearly identified laboratory methods.